10x Genomics (TXG) Liabilities and Shareholders Equity (2018 - 2026)

10x Genomics (TXG) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 12.44% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (up 10.16% YoY), and the FY2025 full-year result was $1.0 billion, up 13.36% from the prior year.
• Liabilities and Shareholders Equity retreated to $1.0 billion in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $903.4 million in Q1 2025.
• A 5-year average of $977.9 million and a median of $989.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity fell 8.99% in 2024 and advanced 13.36% in 2025, its largest moves.
• Tracing TXG's Liabilities and Shareholders Equity over 5 years: stood at $1.0 billion in 2022, then decreased by 6.2% to $965.1 million in 2023, then retreated by 4.82% to $918.6 million in 2024, then increased by 13.36% to $1.0 billion in 2025, then decreased by 2.46% to $1.0 billion in 2026.
• Business Quant data shows TXG's Liabilities and Shareholders Equity at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.